CDXC: ChromaDex Corporation Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 435.95
Enterprise Value ($M) 403.71
Book Value ($M) 34.37
Book Value / Share 0.45
Price / Book 12.68
NCAV ($M) 29.98
NCAV / Share 0.39
Price / NCAV 14.54

Profitability (mra)
Return on Invested Capital (ROIC) 0.04
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.05

Liquidity (mrq)
Quick Ratio 2.35
Current Ratio 2.95

Balance Sheet (mrq) ($M)
Current Assets 52.13
Assets 56.52
Liabilities 22.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
08-21 13D/A Prime Tech Global Ltd 0.00
08-21 13D/A Pioneer Step Holdings Ltd 25.41 144.68

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-3775
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 73,314 392,964 18.66
2025-02-20 114,466 371,559 30.81
2025-02-19 134,544 422,811 31.82
2025-02-18 96,178 450,306 21.36

(click for more detail)

Similar Companies
CASI – CASI Pharmaceuticals, Inc. CDIO – Cardio Diagnostics Holdings, Inc.
CDTX – Cidara Therapeutics, Inc. CELU – Celularity Inc.
CELZ – Creative Medical Technology Holdings, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.